Investor Relations

Eton Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing, acquiring, and commercializing innovative products utilizing the FDA's 505(b)(2) regulatory pathway.

Eton has a diversified pipeline of product candidates under development across various liquid dosage forms, including injectables, oral liquids, and ophthalmics.

Volume :

Copyright West LLC. Minimum 15 minutes delayed.

News Releases
Eton Pharmaceuticals Reports Third Quarter Results and Business Update
December 20, 2018
Licensed High-Value Injectable Product Candidate Successfully Completed Initial Public Offering DEER PARK, Ill. , Dec. 20, 2018 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (NASDAQ: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products,
Read More
Eton Pharmaceuticals Announces Pricing of Initial Public Offering
November 12, 2018
DEER PARK, Ill. , Nov. 12, 2018 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (NASDAQ: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced the pricing of its initial public offering of 3,600,000 shares of its common stock at
Read More
Eton Pharma Reports Positive Top-Line Results from Phase III Trial of EM-100 Ophthalmic Solution
July 24, 2018
DEER PARK, Ill. , July 24, 2018 /PRNewswire/ -- Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, announced positive  top-line results for its phase III study of EM-100 ophthalmic solution. If approved, EM-100 would be the first topical, preservative-free formulation for the treatment
Read More
Email Alerts

Eton
Latest Event

Eton Pharma Reports Positive Top-Line Results from Phase III Trial of EM-100 Ophthalmic Solution
More events are coming soon.